Fortress Biotech, Inc.

FBIO

US34960Q3074

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 03:54:25 2024-05-21 pm EDT			5-day change	1st Jan Change
1.935 ^USD	-0.77%		+9.42%	-36.02%

May. 15	Earnings Flash (FBIO) FORTRESS BIOTECH Posts Q1 Revenue $13M	MT
May. 14	Fortress Biotech Says First Patient Dosed in Phase 2 Study of Triplex	MT

Fortress Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022

November 10, 2022 at 04:01 pm EST

Fortress Biotech, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported revenue was USD 16.12 million compared to USD 19.61 million a year ago. Net loss was USD 10.08 million compared to USD 10.65 million a year ago. Basic loss per share from continuing operations was USD 0.57 compared to USD 1.16 a year ago. Diluted loss per share from continuing operations was USD 0.57.
For the nine months, revenue was USD 57.7 million compared to USD 45.62 million a year ago. Net loss was USD 18.99 million compared to USD 22.24 million a year ago. Basic loss per share from continuing operations was USD 1.09 compared to USD 2.43 a year ago. Diluted loss per share from continuing operations was USD 1.09 compared to USD 2.43 a year ago.

Latest news about Fortress Biotech, Inc.

Earnings Flash (FBIO) FORTRESS BIOTECH Posts Q1 Revenue $13M	May. 15	MT
Fortress Biotech Says First Patient Dosed in Phase 2 Study of Triplex	May. 14	MT
Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver Transplantation	May. 14	CI
North American Morning Briefing : Powell Awaited -2-	Apr. 03	DJ
Certain Warrants of Fortress Biotech, Inc. are subject to a Lock-Up Agreement Ending on 2-APR-2024.	Apr. 01	CI
Certain Options of Fortress Biotech, Inc. are subject to a Lock-Up Agreement Ending on 2-APR-2024.	Apr. 01	CI
Certain Common Stock of Fortress Biotech, Inc. are subject to a Lock-Up Agreement Ending on 2-APR-2024.	Apr. 01	CI
Fortress Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Alliance Global Partners Initiates Fortress Biotech at Buy Rating With $5 Price Target	Mar. 19	MT
Certain Preferred Stock of Fortress Biotech, Inc. are subject to a Lock-Up Agreement Ending on 8-FEB-2024.	Feb. 07	CI
Certain Common Stock of Fortress Biotech, Inc. are subject to a Lock-Up Agreement Ending on 8-FEB-2024.	Feb. 07	CI
Eric Rowinsky Announces Not Stand for Re-Election to the Board of Fortress Biotech, Inc	Jan. 26	CI
Fortress Biotech Prices $11 Million Offering of Stock, Warrants; Shares Sink in Early Trading	Dec. 29	MT
Roth MKM Lowers Price Target on Fortress Biotech to $15 From $30, Maintains Buy Rating	Nov. 29	MT
Top Midday Gainers	Nov. 17	MT
Fortress Biotech Insider Bought Shares Worth $2,664,776, According to a Recent SEC Filing	Nov. 16	MT
Fortress Biotech Insider Bought Shares Worth $249,999, According to a Recent SEC Filing	Nov. 16	MT
Earnings Flash (FBIO) FORTRESS BIOTECH Posts Q3 Revenue $34.8M	Nov. 14	MT
Fortress Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Wall Street Set to Open Slightly Higher as Investors Parse Powell Remarks	Nov. 10	MT
Top Premarket Decliners	Nov. 10	MT
Fortress Biotech Begins Public Offering of Units	Nov. 10	MT
Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 Mg) Vs. Solodyn (Minocycline Hydrochine Hydrochloride Extended-Release Tablets, 105 Mg)	23-10-20	CI
Fortress Biotech Announces 1-for-15 Reverse Stock Split	23-10-09	MT
Avenue Therapeutics, Inc. announced that it expects to receive $0.55 million in funding from Fortress Biotech, Inc. and other investor	23-09-07	CI

Chart Fortress Biotech, Inc.

Duration

Period

More charts

Company Profile

Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has seven marketed prescription pharmaceutical products and over 25 programs in development at the Company, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Such product candidates span six market areas, including oncology, rare diseases and gene therapy. Its dermatology products include Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Exelderm and Luxamend. Its late stage product candidates include Cosibelimab (anti-PD-L1 antibody), DFD-29 (modified release oral minocycline for the treatment of rosacea), CUTX-101 (copper histidinate injection for Menkes disease), IV Tramadol, Olafertinib (also known as CK-101, EGFR inhibitor for EGFR mutation-positive NSCLC), CAEL-101 (monoclonal antibody for AL amyloidosis) and Triplex (cytomegalovirus (CMV) vaccine).

Sector

Pharmaceuticals

Calendar

04:20pm - Alliance Global Partners Healthcare Showcase

More about the company

Income Statement Evolution

More financial data

Ratings for Fortress Biotech, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.95 USD

Average target price

10.75 USD

Spread / Average Target

+451.28%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
FORTRESS BIOTECH, INC.	-36.02%	37.51M
CSL LIMITED	-3.15%	89.69B
SAMSUNG BIOLOGICS CO.,LTD.	+2.50%	41.34B
BIOGEN INC.	-11.83%	33.72B
UCB	+62.74%	26.11B
BIOMARIN PHARMACEUTICAL INC.	-20.08%	14.63B
INCYTE CORPORATION	-8.54%	12.84B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.34%	11.66B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.92%	11.52B
SWEDISH ORPHAN BIOVITRUM AB	+4.27%	8.92B

Biopharmaceuticals